Longidase lyophilisate - official instructions for use. Longidaza, suppositories, injections: instructions for use, indications, contraindications, side effects, dosage Longidaza rectal suppositories instructions for use

Lyophilisate for solution preparation for intramuscular and subcutaneous injection- 1 amp. or fl.:

• active substances: longidase with hyaluronidase activity - 1500 IU - 3000 IU
• excipients: mannitol - up to 15 or 20 mg

In ampoules or vials of neutral glass, in a blister pack 5 ampoules or 5 vials; in a pack of cardboard 1 pack.

Suppositories for vaginal or rectal application- 1 supp.:

• active substances: longidase with hyaluronidase activity - 3000 IU
• excipients: cocoa butter - to obtain a suppository weighing 1.3 g.

In blisters 5 pcs.; in a pack of cardboard 1 or 2 packs.

Description of the dosage form

The lyophilisate for the preparation of a solution for i / m and s / c administration is a porous mass of white or white with a yellowish tint, hygroscopic. Torpedo-shaped suppositories, light yellow in color, with a slight specific smell of cocoa butter, marbling is allowed.

Characteristic

Longidase® is a conjugate of the hyaluronidase enzyme with a water-soluble high molecular weight carrier Polyoxidonium®.

Pharmacokinetics

When administered parenterally, the drug is rapidly absorbed into the systemic circulation and reaches Cmax in the blood after 20-25 minutes, characterized by a high rate of distribution in the body. T1 / 2 (alpha phase) - about 0.5 h, T1 / 2 (beta phase) with different routes of administration - from 42 to 84 hours. It is excreted mainly by the kidneys. In the body, hyaluronidase undergoes hydrolysis, and the carrier breaks down to low molecular weight compounds (oligomers), which are excreted by the kidneys. The drug penetrates into all organs and tissues, incl. passes through the BBB and the blood-ophthalmic barrier. Does not accumulate.

An experimental study of the pharmacokinetics of suppositories with a tritium-labeled enzyme carrier made it possible to establish that, when administered rectally, the drug is characterized by a high distribution rate in the body, is well absorbed into the systemic circulation and reaches Cmax in the blood after 1 hour. The half-distribution period is about 0.5 hours. Bioavailability rectal suppositories Longidases® - not less than 70%.

Pharmacodynamics

Longidase® has enzymatic proteolytic (hyaluronidase) activity, prolonged action, immunomodulatory, chelating, antioxidant and anti-inflammatory properties. The prolongation of the action of the enzyme is achieved by its covalent binding to a physiologically active high molecular weight carrier (Polyoxidonium®), which has its own pharmacological activity.

Longidase® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases depending on the initial level) the synthesis of inflammatory mediators (IL-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection. The covalent bond significantly increases the resistance of the enzyme to denaturing influences and the action of inhibitors: the enzymatic activity of Longidase® is preserved when heated to 37 °C for 20 days, while native hyaluronidase loses its activity during the day under the same conditions.

The covalent bond in the Longidase® preparation ensures the simultaneous local presence of a proteolytic enzyme and a carrier capable of binding the released enzyme inhibitors and collagen synthesis stimulators (iron ions, copper ions, heparin, etc.). Due to these properties, Longidase® has not only the ability to depolymerize the matrix connective tissue in fibrous-granulomatous formations, but also to suppress the reverse (regulatory) reaction aimed at the synthesis of connective tissue components.

The specific substrate of testicular hyaluronidase are glycosaminoglycans ( hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), under the influence of hyaluronidase, glycosaminoglycans lose their basic properties: viscosity, the ability to bind water, metal ions, the formation of collagen proteins into fibers becomes more difficult, the permeability of tissue barriers increases, and the movement of fluid into the intercellular space, the elasticity of the connective tissue increases, which manifests itself in a decrease in tissue swelling, flattening of scars, an increase in the range of motion of the joints, a decrease in contractures and the prevention of their formation, and a decrease in the adhesive process. Biochemical, immunological, histological and electron microscopic studies have shown that Longidaza® does not damage normal connective tissue, but causes destruction of the connective tissue changed in composition and structure in the area of ​​fibrosis.

Longidase® does not have mitogenic, polyclonal activity, does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects. The drug is well tolerated by patients, no local and general allergic reactions were noted. The use of Longidase® in therapeutic doses during or after surgical treatment does not cause worsening of the postoperative period or progression of the infectious process; does not slow down the recovery of bone tissue.

Indications for use Longidaza

Adults in the complex therapy for the treatment and prevention of diseases accompanied by connective tissue hyperplasia.

• in gynecology: treatment and prevention of adhesions in the pelvis with inflammatory diseases internal genital organs, incl. tubal-peritoneal infertility, intrauterine synechia, chronic endometritis;
• in urology: treatment of chronic prostatitis, interstitial cystitis;
• in surgery: treatment and prevention of adhesions after surgical interventions on the abdominal organs; hypertrophic scars after injuries, burns, operations, pyoderma; long-term non-healing wounds;
• in dermatovenereology and cosmetology: treatment of localized scleroderma, keloid, hypertrophic, forming scars after pyoderma, injuries, burns, operations;
• in pulmonology and phthisiology: treatment of pneumosclerosis, fibrosing alveolitis, tuberculosis (cavernous-fibrous, infiltrative, tuberculoma);
• in orthopedics: treatment of joint contractures, arthrosis, ankylosing spondylitis, hematomas;
• to increase bioavailability: when administered together antibacterial drugs in urology, gynecology, surgery, dermatovenereology, pulmonology, to enhance the action of local anesthetics.

Contraindications to the use of Longidaza

• hypersensitivity to drugs based on hyaluronidase;
• acute infectious diseases;
• pulmonary bleeding and hemoptysis;
• fresh hemorrhage in the vitreous body;
• malignant neoplasms;
• kidney failure;
• age up to 18 years (results clinical research absent).

With caution: do not inject the drug into the area of ​​​​acute infectious inflammation (due to the risk of spreading a localized infection); chronic renal failure (used no more than 1 time per week); development allergic reaction(should interrupt the use of the drug).

Before starting treatment, it is necessary to inform the doctor about all drugs taken by the patient.

Longidaza Use in pregnancy and children

Longidase ® should not be used by pregnant women and women during breastfeeding.

Longidaza side effects

Often (>1/100,<1/10) - болезненность в месте введения; иногда (>1/1000, <1/100) - возможны реакции в месте инъекции в виде покраснения кожи, зуда и отека. Все местные реакции угасают через 48–72 ч. Очень редко (<1/10000) - аллергические реакции.

drug interaction

For a lyophilisate for preparing a solution for intramuscular and s / c administration: Longidaza® can be combined with antibiotics, antiviral, antifungal and antihistamines, corticosteroids, bronchodilators, cytostatics. For suppositories: when using Longidase® in patients receiving high doses of salicylates, cortisone, ACTH, estrogens or antihistamines, the effectiveness of the hyaluronidase enzyme may be reduced. When administered in combination with other drugs, the possibility of increasing their absorption (bioavailability) and enhancing systemic action should be considered.

Dosage of Longidase

S / c (near the site of the lesion or under scar tissue) or / m at a dose of 3000 IU, a course of 5 to 25 injections (depending on the severity of the disease) with an interval between injections of 3 to 10 days.

Methods of application are chosen by the doctor depending on the diagnosis, severity of the disease, clinical course, age of the patient.

In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, long-term maintenance therapy with Longidaza® 3000 IU is recommended after a standard course with intervals between injections of 10–14 days.

To increase the bioavailability of drugs, a dose of 1500 IU is recommended with preliminary (10-15 minutes) intramuscular or s / c administration at the same place as the main drug.

Breeding

1. The contents of an ampoule or vial of Longidase ® 3000 IU are dissolved in 1-2 ml of procaine solution (0.25 or 0.5%). In case of intolerance to procaine, Longidaza ® is dissolved in the same volume of sodium chloride solution 0.9% for injection or water for injection.
2. When used to increase bioavailability, the contents of an ampoule or vial of Longidase ® 3000 IU are dissolved in 2 ml, and with a dosage of 1500 IU in 1 ml of a 0.9% sodium chloride solution for injection.

The solvent must be introduced into the vial or ampoule slowly, hold for 2-3 minutes, mix gently without shaking so as not to foam the protein.

The prepared solution for parenteral administration is not subject to storage. Do not administer intravenously!

For the prevention of adhesive disease and gross scarring after surgical interventions on the organs of the abdominal cavity and small pelvis - intramuscularly at a dosage of 3000 IU 1 time in 3 days, a course of 5 injections. If necessary, the use of the drug Longidase ® can be continued with a general course of up to 10 injections with the introduction of 1 time in 5 days.

For treatment

In gynecology:

• adhesive process in the small pelvis with inflammatory diseases of the internal genital organs - intramuscularly at 3000 IU 1 time in 3–5 days, the course is 10–15 injections;
• tubal-peritoneal infertility - intramuscularly at 3000 IU with a total course of up to 15 injections: the first 5 injections - 1 time in 3 days, then - 1 time in 5 days;

In urology:

• chronic prostatitis - IM 3000 IU 1 time in 5 days, course - 10-15 injections;
• interstitial cystitis - IM 3000 IU 1 time in 5 days, course - up to 10 injections;

In surgery:

• adhesive disease after surgical interventions on the abdominal organs - intramuscularly at a dosage of 3000 IU 1 time in 3–5 days, a course of 10 to 15 injections;
• long-term non-healing wounds - intramuscularly at a dosage of 3000 IU 1 time in 5 days, a course of 5-10 injections;

In dermatovenereology, cosmetology:

• limited scleroderma - IM 3000-4500 IU 1 time in 3-5 days, course - up to 20 injections. The dosage and course are selected individually, depending on the clinical course, stage, localization of the disease and the individual characteristics of the patient;
• keloid, hypertrophic and forming scars after pyoderma, burns, operations, injuries - intra-scar or s / c (near the site of the lesion) administration at a dosage of 3000–4500 IU, 1 time in 3 days, a course of up to 15 injections. The volume of dilution of Longidaza ® is chosen by the doctor depending on the number of injection points. If necessary, the course can be continued according to the scheme 1 time in 5 days up to 25 injections. Depending on the area of ​​the skin lesion, the duration of scar formation, it is possible to alternate s / c and / m injections 1 time in 5 days at a dosage of 3000 IU, a course of up to 20 injections.

In pulmonology and phthisiology:

• pneumosclerosis - in / m 3000 IU 1 time in 5 days, course - 10 injections;
• fibrosing alveolitis - intramuscularly at a dosage of 3000 IU 1 time in 5 days, a course of 15 injections, then maintenance therapy - 1 time in 10 days with a total course of up to 25 injections;
• tuberculosis - intramuscularly at a dosage of 3000 IU 1 time in 5 days, a course of up to 25 injections; depending on the clinical picture and the severity of the course of the disease, long-term therapy is possible (from 6 months to 1 year at a dosage of 3000 IU once every 10 days);

In orthopedics:

• joint contracture - s / c near the site of the lesion at a dosage of 3000 IU 1 time in 3 days, the course - from 5 to 15 injections;
• arthrosis, ankylosing spondylitis - s / c near the site of the lesion at a dosage of 3000 IU 1 time in 3 days, a course of up to 15 injections, if necessary, treatment can be continued with injections 1 time in 5 days. The duration of maintenance therapy is chosen by the doctor depending on the severity of the disease;
• hematomas - s / c near the site of the lesion at a dosage of 3000 IU 1 time in 3 days with a course of up to 5 injections;

To increase bioavailability: when administered jointly subcutaneously or intramuscularly with diagnostic or medicinal products (including antibiotics, chemotherapy drugs, anesthetics). Longidase ® is administered 10–15 minutes beforehand at a dosage of 1500 IU in the same way and at the same place as the main drug.

Update: October 2018

Longidase is an effective enzyme preparation with proteolytic, i.e. protein-splitting action, as well as immunomodulatory, anti-inflammatory and antioxidant activity. The drug has a long therapeutic effect.

Two active components in the composition of the drug - azoximer bromide and hyaluronidase, lead to the following positive effects:

• improvement of tissue permeability;
• increased trophism;
• resorption of hematomas;
• reduction of edema;
• increase in tissue elasticity;
• disappearance of adhesions and contractures;
• increased joint mobility;
• suppression of connective tissue growth in scars.

Longidaza is able to bind heavy metals and neutralize toxins. The drug does not have a carcinogenic, mutagenic, toxic and embryotoxic effect on the body and is well tolerated by patients - according to reviews, Longidase injections and suppositories do not give unwanted reactions.

Farmgroup: Preparations with proteolytic activity.

The composition of the drug, physico-chemical properties and price

The drug is produced in two dosage forms: suppositories (method of administration rectally or vaginally) and lyophilisate to obtain a solution for subcutaneous or intramuscular administration.

	suppositories	Lyophilisate
Base substance	Longidase with hyaluronidase activity: 3000 IU	Longidase with hyaluronidase activity 1500 IU (1500 IU ampoules and vials) or 3000 IU ampoules and 3000 IU vials)
Excipients	Cacao butter	Mannitol 15 mg (vials and ampoules 1500 IU) or 20 mg (ampoules and vials 3000 IU)
Physiochemical properties	Candles of an elongated shape, yellowish in color, with a faint smell of cocoa butter. Marble staining of the suppository is acceptable.	The porous hygroscopic mass having white or white-yellow color.
Package	5 suppositories in contour cells, enclosed in cardboard packs.	5 ampoules or vials in blister packs, enclosed in cardboard boxes.
Price	No. 10: 1337-1662 rubles.	Bottles No. 5: 1366-1824 rubles. Ampoules No. 5: 1584-1600 rubles.

pharmachologic effect

The drug has a prolonged enzymatic proteolytic effect. The prolongation of action occurs due to the covalent binding of longidase with a high molecular weight, active carrier (a derivative of poly-1,4-ethylenepiperazine N-oxide), which has pharmacological activity.

The covalent bond ensures the resistance of the enzyme to destructive reactions and the action of inhibitors, as well as the simultaneous local presence of a carrier and a hydrolytic enzyme that binds enzyme inhibitors and activators of collagen synthesis (copper, iron, heparin ions). That is why Longidaza is able to depolymerize the connective tissue matrix in fibrous-granulomatous structures, as well as suppress the regulatory response necessary for the synthesis of connective tissue structural units.

Glycosaminoglycans such as chondroitin, hyaluronic acid, chondroitin-4 and -6-sulfate are specific substrates for testicular hyaluronidase. They form the basis of the connective tissue matrix. As a result of depolymerization under the influence of hyaluronidase, the substrates lose their properties, such as the ability to bind water, viscosity, etc. The conversion of collagen protein into fiber is also difficult, the permeability of tissue barriers increases, the movement of fluid between cells improves and, as a result, the elasticity of the connective tissue improves.

Longidaza helps to reduce the manifestations of the acute phase of inflammation, affects the synthesis of mediators of the inflammatory reaction, increases infectious resistance and enhances the intensity of humoral immunity.

Pharmacokinetics

With the parenteral route of administration, it quickly enters the systemic circulation, reaching a maximum concentration after 20-25 minutes. It is quickly distributed through tissues, penetrates into all organs and structures, including the brain, but does not accumulate.

With rectal and vaginal administration, it also quickly enters the bloodstream, reaching a maximum concentration after 1 hour. The bioavailability of suppositories is 70%. Excreted by the kidneys (half-life is 42-84 hours). Metabolized to low molecular weight oligomers.

Indications for use

It is used in the complex therapy of children from 12 years of age and adults with pathologies that occur with connective tissue hyperplasia. It is also prescribed to improve the bioavailability of diagnostic and therapeutic drugs.

Contraindications

• malignant tumors;
• Pregnancy;
• Children's age up to 12 years;
• Hypersensitivity to Longidase and other drugs with hyaluronidase activity.

In case of insufficiency of kidney function and pulmonary bleeding earlier - appoint no more than 1 time per week.

Lyophilisate

The method of administration and dosing is carried out on an individual basis, based on the severity, clinical pathology and age of the person.

According to the instructions for the use of Longidaza in injections, it is indicated that preliminary preparation of the solution is required. The contents of the vial or ampoule are dissolved in one and a half to two ml of 0.25% or 0.5% procaine solution or in 0.9% NaCl solution, water for injection with intolerance to procaine. The solution cannot be stored, so the field of preparation is introduced immediately.

It is administered subcutaneously near the affected tissue or intramuscularly at a dosage of 3000 IU. In total, 5-15 injections are prescribed with a time interval between each 3-10 days. Repeated course - in 2-3 months.

In pathologies with a severe chronic process of a productive nature in the connective tissue after treatment, maintenance therapy of 3000 IU is prescribed after 10-14 days.

To improve the bioavailability of other drugs: 1500 IU once every 3 days, the total number of injections should not exceed 10.

• Pathologies of the respiratory system: 3000 IU once every 3-5 days - a total of 10 intramuscular injections. Maintenance treatment: 3000 IU once every 10-14 days (up to 12 months).
• Pathologies of the pelvic organs: 3000 IU once every 3-5 days with a course of 5-15 intramuscular injections.
• Scleroderma: 3000-4500 IU once every 3 days with a course of 5-15 intramuscular injections.
• Scars: 3000 IU inside the scar at a dose once or twice a week for 5-10 injections or 3000 IU once every 3-5 days - a total of 10 intramuscular injections.
• Non-scarring wounds: 1500-3000 IU once every 5 days with a course of 5-7 intramuscular injections.
• Arthritis, contractures, hematomas: 3000 IU once or twice a week 7-15 intramuscular injections.
• Adhesive disease: 3000 IU once every 3-5 days 7-15 intramuscular injections.

Candles Longidaza: instructions for use

Assigned for rectal or intravaginal administration once a day at night with a course of 10-20 suppositories. For rectal administration, it is recommended to administer the suppository after a bowel movement. With intravaginal administration - administered in the supine position.

• Urology: 1 suppository every 1 day 10 injections, then 2-3 days later - 10 more injections.
• Gynecology: 1 suppository every two days - 10 injections.
• Dermatovenereology: 1 candle in one or two days. For a course of 10-15 candles.
• Surgery: 1 suppository every two to three days. For a course of 10 candles.
• Pulmonology and Phthisiology: 1 candle every two to four days. For a course of 10-20 suppositories. Supportive treatment - 1 suppository once a week for 3-4 months.

Side effects

• Locally: soreness at the injection site, rarely - hyperemia and swelling of the skin. When using suppositories, itching and swelling at the injection site is occasionally possible.
• Rarely, allergic reactions are possible.
• All side effects disappear after 48-72 hours.

drug interaction

The activity of Longidase decreases with simultaneous treatment with estrogens, salicylates, cortisone, ACTH, antihistamines in high doses. An increase in the bioavailability of the second drug should be taken into account when used simultaneously with Longidase.

special instructions

Longidase should not be injected into the area of ​​acute or infectious lesions. In the treatment of acute foci of infection, antimicrobial agents are simultaneously prescribed.

With the development of any allergic reaction, the drug is canceled.

Overdose

No such cases have been recorded.

Analogues:

A similar composition has Lidaza (10 amp. 200 rubles), Lidaza - M and Ronidaza.

Instructions for use of Longidaza® vaginal and rectal suppositories 3000 ME

Registration number: LSR-002940/07

Trade name: Longidaza®

International non-proprietary name: Bovhyaluronidase azoximer (bovhyaluronidasum azoximerum)

Chemical name: hyaluronidase conjugate with a copolymer of 1,4-ethylenepiperazine N-oxide and (N-carboxymethyl)-1,4-ethylenepiperazinium bromide

Dosage form: suppositories vaginal and rectal

Composition per suppository:

Active substance: Bovhyaluronidase azoximer (Longidase®) - 3000 IU

Auxiliary substance: cocoa butter - to obtain a suppository weighing 1.3 g

Description: torpedo-shaped suppositories, light yellow in color with a slight specific smell of cocoa butter, marbling is allowed.

Pharmacotherapeutic group: enzymatic agent

ATX code: V03AX

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS

Longidase® has hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory properties.

Prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azoxymer). Longidase® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection.

The pronounced antifibrotic properties of Longidase are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors: the enzymatic activity of Longidase is preserved when heated to 37 ° C for 20 days, while native hyaluronidase loses its activity under the same conditions. during the day. In Longidase®, the simultaneous local presence of the hyaluronidase enzyme and a carrier is ensured, which is capable of binding the enzyme inhibitors released during hydrolysis of the matrix components and stimulators of collagen synthesis (iron ions, copper ions, heparin, etc.). Due to these properties, Longidase® has not only the ability to depolymerize the connective tissue matrix in fibrous-granulomatous formations, but also to suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.

Glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix, are a specific substrate for testicular hyaluronidase. As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, and the elasticity of connective tissue increases , which manifests itself in a decrease in tissue swelling, flattening of scars, an increase in the range of motion of the joints, a decrease in contractures and the prevention of their formation, and a decrease in the adhesive process. Biochemical, immunological, histological and electron microscopic studies have shown that Longidaza® does not damage normal connective tissue, but causes destruction of the connective tissue changed in composition and structure in the area of ​​fibrosis.

Longidase® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The drug is well tolerated by patients, no local and general allergic reactions were noted.

The use of Longidaza in therapeutic doses during or after surgical treatment does not cause a deterioration in the course of the postoperative period or the progression of the infectious process; does not slow down the recovery of bone tissue.

PHARMACOKINETICS

An experimental study of pharmacokinetics made it possible to establish that, when administered rectally, Longidase® is characterized by a high distribution rate in the body, is well absorbed into the systemic circulation and reaches its maximum concentration in the blood after 1 hour.

The half-life is about 0.5 hours, the half-life is from 42 to 84 hours. It is excreted mainly by the kidneys.

The drug penetrates into all organs and tissues, including passing through the blood-brain and blood-ophthalmic barriers. The absence of tissue cumulation was established.

The bioavailability of the drug Longidase® with rectal administration is high: about 90%.

Indications for use

Adults and adolescents over 12 years of age as monotherapy and as part of complex therapy for diseases accompanied by connective tissue hyperplasia, including against the background of an inflammatory process:

CONTRAINDICATIONS

• hypersensitivity to drugs based on hyaluronidase
• pulmonary hemorrhage and hemoptysis
• fresh vitreous hemorrhage
• malignant neoplasms

• acute renal failure
• children under 12 years of age (no clinical trial results)
• pregnancy and breastfeeding period

CAREFULLY

Use with caution more than once a week in patients with chronic renal failure, history of pulmonary bleeding.

USE IN PREGNANCY AND DURING BREASTFEEDING

Use during pregnancy and during breastfeeding is contraindicated (clinical experience is not available).

Teenagers from 12 to 18 years old suppositories are administered only rectally.

Adults and adolescents over 12 years of age, rectally: 1 suppository 1 time per day after bowel cleansing.

Adults vaginally: 1 suppository 1 time per day (at night), the suppository is inserted into the vagina in the supine position.

The scheme of administration is adjusted depending on the severity, stage and duration of the disease: Longidaza® is prescribed every other day or at intervals of 2-3 days.

in pulmonology and phthisiology: 1 suppository every 2-4 days 10-20 injections

in surgery: 1 suppository every 2-3 days 10 injections

in gynecology: rectally or vaginally 1 suppository every 2 days 10 injections, then maintenance therapy is prescribed if necessary

Side effect

The frequency of adverse reactions is presented according to the following classification: very frequent ≥ 10%; frequent ≥ 1% and

Very rarely: local reactions in the form of redness, swelling, itching of the perianal zone, vaginal itching due to individual sensitivity to the components of the drug.

Overdose

Overdose symptoms may include chills, fever, dizziness, and hypotension. The introduction of the drug is stopped and symptomatic therapy is prescribed.

INTERACTION WITH OTHER DRUGS

Longidase® can be combined with antibiotics, antiviral, antifungal drugs, bronchodilators. When administered in combination with other drugs (antibiotics, local anesthetics, diuretics), the possibility of increasing bioavailability and enhancing their action should be considered.

When used together with large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines, the enzymatic activity of Longidase® may be reduced.

Do not use the drug Longidase® simultaneously with drugs containing furosemide, benzodiazepines, phenytoin.

SPECIAL INSTRUCTIONS

When taking the drug, strictly follow the instructions given in the instructions.
If you have any questions, ask your doctor or pharmacist for clarification.

• If an allergic reaction develops, stop using Longidaza®.
• When used against the background of exacerbation of foci of infection to prevent the spread of infection, it is necessary to prescribe under the cover of antimicrobial agents.
• If adverse reactions occur, as well as if an adverse reaction occurs that is not mentioned in the instructions for medical use, you should contact your doctor.
• Do not use the drug if there are visual signs of its unsuitability (packaging defect, discoloration of the suppository).
• In case of missing the next dose of the drug, continue to use it as usual (do not administer a double dose).
• If it is necessary to stop taking the drug Longidase®, cancellation can be carried out immediately, without a gradual dose reduction.